As shown in Fig. 3f, for the FCS/aPDL1 treated group, the percentages of both CD4+ and CD8+ T cells showed an obvious increase in the tumor, indicating that aPDL1 was successfully delivered into the tumor to revert the T cell exhaustion. The gene discussed is CD4; the disease is neoplasm.